Novartis Secures Ophthalmic Diversity With Final Alcon Buyout
Executive Summary
Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward